/
Oncology
Relapsed/refractory Hematological Malignancies
5
Pipeline Programs↗
4
Active Trials↗
7
Companies Involved↗
Relapsed/Refractory Hematological Malignancies is an early-stage landscape with 5 programs across 7 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Ascentage Pharma Group Inc., Qilu Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 15
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
4 of 5 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Analysis
Trial Status
8
clinical trials
Recruiting3 · 38%
Completed3 · 38%
Unknown status1 · 13%
Not yet recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Recruiting·—·Phase 1·NCT05528887·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)